Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

Safety Information

A6226

Sigma-Aldrich

AM251

>98% (HPLC), solid, cannabinoid receptor (CB1) antagonist

Synonym(s):

1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C22H21N4OCl2I
CAS Number:
183232-66-8
Molecular Weight:
555.24
MDL number:
MFCD01861181
UNSPSC Code:
12352200
PubChem Substance ID:
24891069
NACRES:
NA.77

Product Name

AM251, >98% (HPLC), solid

Quality Level

100

Assay

>98% (HPLC)

form

solid

color

white

solubility

DMSO: >10 mg/mL
H2O: insoluble

originator

Sanofi Aventis

SMILES string

Cc1c(nn(-c2ccc(Cl)cc2Cl)c1-c3ccc(I)cc3)C(=O)NN4CCCCC4

InChI

1S/C22H21Cl2IN4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-7-16(23)13-18(19)24)21(14)15-5-8-17(25)9-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)

InChI key

BUZAJRPLUGXRAB-UHFFFAOYSA-N

Gene Information

mouse ... Cnr1(12801) , Cnr2(12802)
rat ... Cnr1(25248)

Application

AM251, a CB1 cannabinoid receptor antagonist, has been used in a study to determine its interaction with hippocampal neurons to enhance spatial memory in mice.

Biochem/physiol Actions

AM251 is a CB1 cannabinoid receptor antagonist.

Features and Benefits

This compound is featured on the Cannabinoid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Other Notes

Salt content may vary.

Hazard Statements

H413

Precautionary Statements

P273 - P501

Hazard Classifications

Aquatic Chronic 4

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

ISHL Indicated Name

Substances Subject to be Indicated Names

ISHL Notified Names

Substances Subject to be Notified Names

JAN Code

A6226-BULK-CR:
A6226-IP:
A6226-50MG:4548173990279
A6226-VAR:
A6226-10MG:4548173990262
A6226-BULK:

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
056M4611V
084M4610V
082M4621V
090M4624
098K46192

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Loren J Martin et al.
Current biology : CB, 29(2), 192-201 (2019-01-15)
Pain memories are hypothesized to be critically involved in the transition of pain from an acute to a chronic state. To help elucidate the underlying neurobiological mechanisms of pain memory, we developed novel paradigms to study context-dependent pain hypersensitivity in
Nozomi Asaoka et al.
The Journal of toxicological sciences, 41(6), 813-816 (2016-11-18)
N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-3-methyl-D-valine methyl ester (5F-ADB) is one of the most potent synthetic cannabinoids and elicits severe psychotic symptoms in humans, sometimes causing death. To investigate the neuronal mechanisms underlying its toxicity, we examined the effects of 5F-ADB on midbrain dopaminergic and
Danilo De Gregorio et al.
Pain, 160(1), 136-150 (2018-08-30)
Clinical studies indicate that cannabidiol (CBD), the primary nonaddictive component of cannabis that interacts with the serotonin (5-HT)1A receptor, may possess analgesic and anxiolytic effects. However, its effects on 5-HT neuronal activity, as well as its impact on models of
Ramy Khella et al.
Psychopharmacology, 231(16), 3071-3087 (2014-04-08)
Whilst cannabinoid CB2 receptors were thought to exist predominantly in immune cells in the periphery, the recent discovery of CB2 receptors in the brain has led to an increased interest in the role of these central CB2 receptors. Several studies
Elahe Mohammadi Vosough et al.
Life sciences, 232, 116670-116670 (2019-07-23)
Migraine is a neurological debilitating disorder. Previous studies have shown that cannabinoid receptor agonists have analgesic effects in various models of pain. In this study, therefore, we investigated anti-nociceptive effects of WIN 55,212-2, and the role of either CB1 or
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service